Venus Concept's Pain Management Device Scores FDA Nod

by Vandana Singh, Benzinga Editor

October 19, 2021 3:39 PM | 1 min read |

The FDA has given 510(k) clearance to Venus Concept Inc's VERO Venus Freedom device for pain management.
Venus Freedom is a noninvasive, non-ablative device with three applicators to deliver non-thermal radiofrequency energy combined with massage and magnetic field pulses.
It is intended for minor muscle aches & pain, relief of muscle spasms, and temporary improvement of local blood circulation.
Related: Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook.
The Company will commence a limited launch of Venus Freedom in the U.S. during Q1 of 2022.
Price Action: VERO shares are up 2.50% at $2.05 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.